Effect of long-term administration of Hexarelin on the somatotrophic axis in aged rats.

Cattaneo L, Luoni M, Settembrini B, Müller EE, Cocchi D

Pharmacological research1 Jul 1997Cited by 7 (Europe PMC)

PMID9368914DOI10.1006/phrs.1997.0203PepBankPUB-09368914

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In old rats, the GH-releasing effect of hexarelin was maintained during chronic treatment.
In plain wordsIn old rats, hexarelin kept releasing growth hormone during 30 to 60 days of treatment.
Peptide
Hexarelin
Outcome
No significant changePersistence of GH-releasing effect during chronic treatment
Study
ratn: not reported in source
Aged rats
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
80 micrograms/kg · subcutaneous · 30 and 60 daysAs given in this study (rat).
Source sentences
Summary
The GH-releasing effect of Hexa was maintained during chronic treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
The growth hormone-releasing peptide Hexarelin (Hexa; 80 micrograms/kg-1, s.c.) was administered for 30 and 60 days to old rats.
Report a problemFND-0936891401
02AnimalAnimal study (in vivo)Efficacy outcome
In old rats, a hexarelin dose elicited a greater GH response in rats chronically treated with hexarelin than in rats given placebo.
In plain wordsIn old rats, a hexarelin dose released more growth hormone in rats treated long term with hexarelin than in rats given placebo.
Peptide
Hexarelin
Outcome
IncreaseGH response to a final hexarelin dose after chronic treatment
Study
ratn: not reported in source
Aged rats
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
80 micrograms/kg · subcutaneous · 30 and 60 daysAs given in this study (rat).
Source sentences
Summary
At the end of the treatment, old rats were administered once with Hexa which elicited a greater GH response in rats chronically treated with the peptide than in those receiving a placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
The growth hormone-releasing peptide Hexarelin (Hexa; 80 micrograms/kg-1, s.c.) was administered for 30 and 60 days to old rats.
Report a problemFND-0936891402
03AnimalAnimal study (in vivo)Efficacy outcome
In rats, pituitary GH mRNA was lower in older than in younger animals, irrespective of hexarelin treatment.
In plain wordsIn rats, hexarelin treatment did not change the lower pituitary growth hormone mRNA seen in older animals.
Peptide
Hexarelin
Outcome
No significant changePituitary GH mRNA concentration
Study
ratn: not reported in source
Aged rats
Comparator
Untreated old rats
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
80 micrograms/kg · subcutaneous · 30 and 60 daysAs given in this study (rat).
Source sentences
Summary
Pituitary GHmRNA concentrations were significantly lower in the older rats than in the younger animals, irrespective of Hexa treatment, while the GH protein content was similar in all the groups studied.
1 context sentence(design, population, supporting numbers)
Summary · context
The growth hormone-releasing peptide Hexarelin (Hexa; 80 micrograms/kg-1, s.c.) was administered for 30 and 60 days to old rats.
Report a problemFND-0936891403
04AnimalAnimal study (in vivo)Efficacy outcome
In rats, pituitary GH protein content was similar in all groups studied.
In plain wordsIn rats, pituitary growth hormone protein content was similar in all groups, with or without hexarelin.
Peptide
Hexarelin
Outcome
No significant changePituitary GH protein content
Study
ratn: not reported in source
Aged rats
Comparator
Untreated old rats
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
80 micrograms/kg · subcutaneous · 30 and 60 daysAs given in this study (rat).
Source sentences
Summary
while the GH protein content was similar in all the groups studied.
1 context sentence(design, population, supporting numbers)
Summary · context
The growth hormone-releasing peptide Hexarelin (Hexa; 80 micrograms/kg-1, s.c.) was administered for 30 and 60 days to old rats.
Report a problemFND-0936891404
05AnimalAnimal study (in vivo)Efficacy outcome
In old rats, hypothalamic GHRH synthesis was reduced in all older animals, with no sign that hexarelin changed it.
In plain wordsIn old rats, hexarelin did not change the reduced GHRH production in the hypothalamus.
Peptide
Hexarelin
Outcome
No significant changeHypothalamic GHRH synthesis
Study
ratn: not reported in source
Aged rats
Comparator
Untreated old rats
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
80 micrograms/kg · subcutaneous · 30 and 60 daysAs given in this study (rat).
Source sentences
Summary
Pituitary GHmRNA concentrations were significantly lower in the older rats than in the younger animals, irrespective of Hexa treatment, while the GH protein content was similar in all the groups studied. The same was true for hypothalamic GHRH, whose synthesis was reduced in all the older animals bu…
1 context sentence(design, population, supporting numbers)
Summary · context
The growth hormone-releasing peptide Hexarelin (Hexa; 80 micrograms/kg-1, s.c.) was administered for 30 and 60 days to old rats.
Report a problemFND-0936891405
06AnimalAnimal study (in vivo)Efficacy outcome
In rats, hypothalamic GHRH peptide concentrations were maintained in the older animals.
In plain wordsIn rats, hypothalamic GHRH peptide concentrations were maintained in older animals.
Peptide
Hexarelin
Outcome
No significant changeHypothalamic GHRH peptide concentration
Study
ratn: not reported in source
Aged rats
Comparator
Untreated old rats
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
80 micrograms/kg · subcutaneous · 30 and 60 daysAs given in this study (rat).
Source sentences
Summary
in the presence of maintained concentrations of the peptide.
1 context sentence(design, population, supporting numbers)
Summary · context
The growth hormone-releasing peptide Hexarelin (Hexa; 80 micrograms/kg-1, s.c.) was administered for 30 and 60 days to old rats.
Report a problemFND-0936891406
07AnimalAnimal study (in vivo)Efficacy outcome
In old rats, hexarelin for 30 or 60 days brought the raised hypothalamic somatostatin mRNA down to young levels.
In plain wordsIn old rats, 30 or 60 days of hexarelin brought somatostatin mRNA in the hypothalamus back to the level of young rats.
Peptide
Hexarelin
Outcome
DecreaseHypothalamic somatostatin mRNA
Study
ratn: not reported in source
Aged rats
Comparator
Untreated old rats
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
80 micrograms/kg · subcutaneous · 30 and 60 daysAs given in this study (rat).
Source sentences
Summary
Somatostatin mRNA concentrations were significantly higher in the hypothalami of older rats and administration of Hexa for 30 or 60 days brought the concentrations of somatostatin mRNA of aged rats to 'young' levels.
1 context sentence(design, population, supporting numbers)
Summary · context
The growth hormone-releasing peptide Hexarelin (Hexa; 80 micrograms/kg-1, s.c.) was administered for 30 and 60 days to old rats.
Report a problemFND-0936891407
08AnimalAnimal study (in vivo)Efficacy outcome
In old rats, hexarelin treatment did not change circulating IGF-1 levels.
In plain wordsIn old rats, hexarelin treatment did not change IGF-1 levels in the blood.
Peptide
Hexarelin
Outcome
No significant changeCirculating IGF-1
Study
ratn: not reported in source
Aged rats
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
80 micrograms/kg · subcutaneous · 30 and 60 daysAs given in this study (rat).
Source sentences
Summary
Treatments with Hexa failed to alter the circulating levels of IGF-1.
1 context sentence(design, population, supporting numbers)
Summary · context
The growth hormone-releasing peptide Hexarelin (Hexa; 80 micrograms/kg-1, s.c.) was administered for 30 and 60 days to old rats.
Report a problemFND-0936891408

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.